ABSTRACT Estimation of drug efficacy in antimalarial drug trials requires parasite genotyping to distinguish new infections from treatment failures. When using length-polymorphic molecular markers, preferential amplification of short fragments can compromise detection of coinfections, potentially leading to misclassification of treatment outcome. We quantified minority clone detectability and competition among msp1, msp2, and glurp amplicons using mixtures of Plasmodium falciparum strains and investigated the impact of template competition on genotyping outcomes in 44 paired field samples. Substantial amplification bias was detected for all three markers, with shorter fragments outperforming larger fragments. The strongest template competition was observed for the marker glurp. Detection of glurp fragments in multiclonal infections was severely compromised. Eight of 44 sample pairs were identified as new infections by all three markers. Ten pairs were defined as new infections based on one marker alone, seven of which were defined by the questionable marker glurp. The impact of size-dependent template competition on genotyping outcomes therefore calls for necessary amendments to the current WHO recommendations for PCR correction of malaria drug trial endpoints. Accuracy of genotyping outcomes could be improved by separate amplification reactions per allelic family and basing results on markers msp1 and msp2 first, with glurp only used to resolve discordant results.
I
n areas of high malaria endemicity, individuals are often multiply infected with Plasmodium falciparum. The number of concurrent clones per infected individual is denoted the multiplicity of infection (MOI). The MOI can reach a mean of five clones per infection in high-transmission areas and usually ranges between one and two clones per infected individual in regions of intermediate or low transmission (1) . Concurrent clones in multiclone infections are distinguished by genotyping of polymorphic molecular markers. In in vivo efficacy drug or vaccine trials in settings where malaria is endemic, parasite genotyping for discrimination of newly incoming versus recrudescent clones after antimalarial treatment is essential for accurate estimation of the efficacy of the intervention (2, 3) . Genotyping is further used in malaria molecular epidemiology to assess MOI as a proxy of transmission level in molecular monitoring of interventions and for tracking of individual clones over time in cohort studies to measure the molecular force of infection or duration of infection (4, 5) .
The most commonly used P. falciparum molecular markers for genotyping are the length-polymorphic genes encoding the merozoite surface proteins 1 and 2 (msp1 and msp2) and the glutamate-rich protein (glurp) (6, 7) . The adoption of capillary electrophoresis (CE)-based sizing of PCR products largely resolved limitations of gel-based sizing protocols, such as insufficient resolution of minimal size differences, particularly among fragments larger than 500 bp, or unequal loading of variable PCR yields leading to apparent but artificial size differences. These limitations are particularly relevant for glurp genotyping, since amplicons of the glurp R2 region often surpass 1,000 bp in size, and CE-based glurp genotyping was not routinely used in most laboratories (8, 9) .
Parasite clones occasionally remain undetected by PCR despite persisting in a host, an observation described as imperfect clone detectability. The detectability of a clone in an individual sample has been estimated at around 60% in young children from Papua New Guinea (10) and Ghana (5, (11) (12) (13) (14) and was found to decrease to 20% in Ghanaian adults older than 60 years (5, (11) (12) (13) (14) . Imperfect detectability is often attributed to periodical sequestration or fluctuations of parasite densities around the detection limit of PCR as a consequence of naturally acquired immunity to variant antigens. How much technical reasons contribute to imperfect detectability of individual clones has not been investigated systematically for the three prime P. falciparum genotyping markers msp1, msp2, and glurp, but circumstantial observations of clone competition during PCR can be found in the literature (15, 16) .
Template competition among differently sized amplicons during PCR as well as the presence of a predominant clone might limit detectability of minority clones in multiclonal infections. This study thus aimed to improve the accuracy of the recommended genotyping procedures for P. falciparum typing routinely applied in malaria drug trials (17) and to establish the dimension of technical limitations in genotyping of recurrent parasitemias. The present findings indicate a dramatic effect of competition during PCR in favor of the smallest fragment.
RESULTS
glurp genotyping. We observed significant preferential amplification of the shorter fragment in mixtures of two P. falciparum laboratory strains, 3D7 and HB3, carrying different glurp alleles. For the 1:1 ratio, only the shorter HB3 amplicon 537 bp in size was visible after fragment separation on agarose gel (Fig. 1A) . The longer 3D7 fragment (881 bp) was only detected if present at least 5-fold in excess over the shorter fragment (Fig. 1A) . The HB3 minority clone demonstrated stronger bands than the 3D7 dominant clone up to a HB3/3D7 ratio of 1:10. In the reciprocal dilution series with HB3 as the dominant clone, amplification of the longer 3D7 fragment was completely suppressed by the shorter HB3 amplicon (Fig. 1B) . The accuracy and precision of glurp sizing were substantially improved by CE compared to agarose gel, but due to the high fluorescence cutoff required to account for characteristic high stutter peaks in glurp PCR-CE, the detectability of minority clones was not increased. msp1 and msp2 genotyping. Unlike glurp, the alleles of markers msp1 and msp2 fall into three and two allelic families, respectively (Table 1) . When family-specific msp1 or msp2 nested PCRs (nPCRs) were initially multiplexed, pronounced competition between templates was observed irrespective of whether clones belonged to the same or different allelic families. For example, in msp2 PCR using mixtures of 3D7 (3D7 type) and HB3 (Fc27 type), the minority clone was only detected in ratios up 1:250. To avert such template competition, at least for allele mixtures of different families, all msp1 and msp2 nPCRs were performed as simplex family-specific reactions. This strategy increased clone detectability in mixtures of alleles from alternative families drastically, so that the minority clone was detected in all ratios up to 5,000:1 for markers msp1 and msp2 ( Fig.  2A and B, right panels). However, template competition will still persist if alleles of the same family occur together.
When two mixed strains carried msp1 or msp2 alleles from the same allelic family, the shorter fragment was always preferentially amplified in 1:1 ratios (Fig. 3) . The extent of template competition between alleles of the same family was quantified in a systematic analysis of different ratios of two culture strains, which showed that amplicon size had a dramatic effect on PCR outcome (Fig. 2) . In mixtures of strains K1 and 3D7, which harbor msp1 alleles of the same allelic family, the small msp1 K1 allele (177 bp) was still detected in a 500-fold underrepresentation. In the reciprocal dilution with K1 as the dominant clone, the longer 3D7 allele (248 bp) was only detectable up to a K1/3D7 dilution ratio of 5:1 ( Fig. 2A, left panel) . A similar picture was observed for the Mad20-type msp1 family: the shorter HB3 allele was detectable even if 200-fold underrepresented, but vice versa, the longer FCB1 allele was only detectable if it was no more than 5-fold underrepresented ( Fig. 2A, middle panel) . Results for marker msp2 mirrored findings from msp1 in that the shorter allele was preferentially amplified in PCR (Fig. 2B) .
CE peak heights did not reflect the ratio of strains mixed ( Fig. 3 ; see Fig. S1 in the supplemental material). The proportions of fluorescent signal from the minority versus dominant clone (Fig. S1 ), as well as the relative detection limit of a minority clone (Fig.  2) , differed between markers and allelic families. msp2 fragment lengths as well as the size differences between msp2 alleles were larger than those of msp1, and coherently, the detection limit of msp2 minority clones was reached at lower ratios than msp1 genotyping (Fig. 2) . Not only the size difference between amplicons but also overall PCR fragment size may thus contribute to the observed amplification bias.
glurp clone detectability in mixtures of four culture strains. Complex ratios of four culture strains were also assessed. In a 1:1:1:1 mixture of strains, glurp fluorescent signal and thus the relative proportion of amplified fragments decreased with increasing amplicon size (Fig. 4A) . A 2-fold overrepresentation of the clone with the shortest glurp allele (HB3, 537 bp) led to complete suppression of all other fragments after applying the peak height cutoff (Fig. 4B , left panel). In contrast, when strain 3D7 (carrying the longest glurp fragment) increased in abundance, it remained undetected The extent of template competition between several concurrent clones in msp1 and msp2 PCR depends largely on the composition of allelic families in the mixture. For a reliable assessment of amplification bias among more than two alleles per family of msp1 and msp2, a large number of different culture strains would be required.
Genotyping of field samples. Marker performance was compared in genotyping of recurrent parasitemias using 44 paired pre-and posttreatment field samples. The mean msp2 MOI was slightly higher after simplex allelic family-specific nPCR compared to duplex nPCR (2.2 versus 2.0 clones/infection). With a mean MOI of 1.4 clones per infection, glurp consistently identified fewer coinfecting clones compared to markers msp1 and msp2 (simplex nPCRs; mean msp1 and msp2 MOI of 2.2 clones/infection). Particularly in samples with a high msp1 or msp2 MOI, minority clone detection by marker glurp was severely limited (Fig. 5A) . The mean number of clones detected did not differ between recrudescences and new infections for any marker ( Fig. 5B ; Wilcoxon P value of Ͼ0.05).
Genotyping outcomes of all three markers, msp1, msp2, and glurp, agreed for 30/44 (68%) of sample pairs, whereby 22 clear recrudescences and 8 clear new infections were identified (Table 2) . When applying the current WHO-recommended approach of typing markers sequentially, all remaining 14 infections were characterized as new infections (Table 2) . However, for 7/14 sample pairs, this classification was only supported by questionable marker glurp, while both msp1 and msp2 denoted a recrudescence. This suggests false classification due to imperfect glurp minority clone detectability using the current classification approach. A more appropriate classification would be based on the two better-performing markers msp1 and msp2, which would diagnose these 7 pairs as recrudescence. For the remaining 7/14 sample pairs, markers msp1 and msp2 Size-Dependent Template Competition in PCR Antimicrobial Agents and Chemotherapy gave disparate results. Two approaches were tested for final classification of these seven sample pairs: first, our proposed approach 1 is based on support from two out of three markers msp1, msp2, and glurp; second, our proposed approach 2 is based on markers msp1 and msp2 only, but defining as a decisive characteristic for a new infection a complete switch in allelic family between the pre-and posttreatment samples. In other words, a sample pair was only characterized as a new infection if all alleles detected in the posttreatment sample were different from those in the pretreatment sample and belonged to an allelic family not present in the pretreatment sample. These approaches classified 3/7 (approach 1) or 4/7 (approach 2) sample pairs as recrudescence (see Table S3 in the supplemental material). In total, 75% (32/44 using approach 1 and 33/44 using approach 2) of recurrent parasitemias after treatment were defined as recrudescent when using the proposed approaches for classification (Table 2 ). In contrast, only 50% (22/44) would be defined as recrudescent when one marker alone (in 7/14 cases, this was marker glurp) was permitted to define a new infection. This suggests misclassification of a third of all recrudescences as new infections by the current approach, mainly due to the marker glurp.
DISCUSSION
The present study allowed investigation of the impact of PCR amplification bias in a controlled environment, revealing a bias more severe than anticipated. A great advantage of shorter over longer fragments was confirmed, with the strongest effect observed for the marker glurp. This is likely due to the overall larger glurp PCR fragments (within this study, 537 to 1,111 bp) compared to msp1 (149 to 275 bp) or msp2 (205 to 506 bp). glurp PCR was also more prone to produce stutter peaks, which cannot easily be distinguished from peaks of minority clones, particularly if a dominant clone is present in a sample. Due to the pronounced stutter peaks in glurp PCR, the CE peak height cutoff (applied to prevent mistaking stutter peaks for true fragments) had a n, number of sample pairs per pattern. b NI, new infection; R, recrudescence. c The current approach to define the overall genotyping result as recommended by WHO uses sequential typing-i.e., stopping the genotyping procedure at first indication of a new infection using markers in the order msp2, msp1, and glurp. d New approach 1 proposed in this study is based on forming a consensus result: i.e., the result obtained by 2 out of the 3 markers, msp1, msp2, and glurp. e New approach 2 proposed in this study is based solely on markers msp1 and msp2 and compares the compositions of allelic families between pre-and posttreatment samples. A sample pair is only classified as NI if all allelic families differ between between the pre-and posttreatment samples for one of the markers, msp1 or msp2. Detailed genotyping data and classification of these samples are shown in Table S3 in the supplemental material.
to be increased for glurp PCR compared to msp1 or msp2 PCR. As result, true peaks of minority clones are more likely to fall below the cutoff and thus remain undetected in glurp PCR, leading to underestimation of MOI. An essential observation was the importance of performing simplex allelic familyspecific nPCRs for both msp markers, whenever increased precision is required. The use of allelic family-specific primers to increase sensitivity and resolution of genotyping in samples containing clones from different allelic families has been proposed previously (2, 7, 18) . Our results, however, emphasize that unless nPCRs are performed separately, the gain in minority clone detectability using allelic family-specific primers is marginal. A great gain in sensitivity is observed when nPCRs are performed separately, which justifies the increase in diagnostic cost. Yet, template competition between alleles from the same family cannot be overcome even by simplex nPCR. Marker glurp with only one allelic family and longest amplicon sizes can thus be considered the least suitable marker for sensitive discrimination of clones. Studies performed before the adoption of CE-based genotyping methods used PCR-restriction fragment length polymorphism (PCR-RFLP) to distinguish msp2 clones (19) . This protocol did not use family-specific msp2 primers; therefore, all amplified fragments (ranging from 350 to 750 bp) likely were also subject to amplification bias. Yet, fragments on average were substantially smaller than glurp fragments, which ranged from 537 to 1,111 bp in this study.
The significantly lower MOI observed in our field samples using marker glurp compared to msp1 and msp2 could be due to a lower diversity of glurp, but a major factor seems to be suppression of minority clones or long fragments during glurp PCR. In light of the severe bias in glurp PCR in artificial mixtures of culture strains, new infections identified only by glurp genotyping and not by the other two markers are probably attributable to competition in PCR and should be interpreted with care. It is therefore crucial to consider PCR limitations such as amplification bias when designing a strategy for genotyping and data analysis.
The WHO definition of a recrudescent infection is the presence of at least one shared genotype in the compared pre-and posttreatment samples at all loci. A new infection is defined by the presence of only new alleles in the posttreatment sample by at least one of the markers (3). The effects of intra-allelic family competition during PCR demonstrated here suggest a reconsideration of the current recommended genotyping procedure, which stipulates consecutive analysis of the three markers. According to the current strategy, once a new infection is observed by one of the markers the remaining loci are not typed. In contrast, if amplification of both msp markers with family-specific simplex nPCRs was mandatory, minority clone detectability would be drastically increased due to (i) the lower likelihood of two clones to harbor alleles of the same msp1 as well as the same msp2 family, and (ii) the independence of allele sizes of msp1 and msp2 for any given clone, making it unlikely that alleles of both markers will be suppressed during PCR.
Marker glurp, despite its shortfalls, might be useful until a more suitable marker is found and validated, as it can provide additional resolution in areas of low transmission with only limited diversity in both msp markers. In contrast, in study areas with high mean MOI, glurp likely contributes to overestimation of new infections, as later recrudescing minority clones could easily be missed in a multiclonal admission sample. The use of glurp as a third marker should hence be critically reviewed, and its application could be restricted to drug trials performed in low-endemicity settings. Furthermore, a more robust definition of "new infection" should be discussed among experts, which could be primarily, or exclusively, based on markers msp1 and msp2. In practice, genotyping of recurrent parasitemias should therefore begin with typing both markers msp1 and msp2. If these two markers agree, glurp genotyping would no longer be necessary. In case of a disagreement between msp1 and msp2 genotyping outcomes, either glurp typing would have to be performed and the "two out of three" rule applied (preferred in low-endemicity settings), or the composition of allelic msp1 and msp2 families would be considered (preferred in high-endemicity settings). In the latter approach, final classification as a new infection would require a complete shift of allelic families between pre-and posttreatment samples for either msp1 or msp2, as clone competition is abrogated between allelic families if nPCRs are performed as simplex PCRs.
In summary, the following alterations of the current genotyping strategy could be considered: (i) separate nPCRs for each allelic family, (ii) obligate genotyping of the two markers msp1 and msp2, or (iii) classification of recurrent parasitemias based on a consensus result of markers msp1 and msp2 first, with disparate msp1 and msp2 results resolved using marker glurp or, as potentially the best option, by rating msp1/msp2 allelic families for defining a new infection.
In areas where malaria is highly endemic, with frequent multiclone infections, these amendments could affect the outcome of drug efficacy trials in that less recrudescent infections would be misclassified as new infections, and in consequence, overestimation of the efficacy of a tested drug would be reduced.
In the future, such technical limitations might be overcome by the development of single-nucleotide polymorphism-based genotyping techniques, which, in combination with molecular barcoding or next-generation sequencing, might provide highly diverse haplotype markers with sufficient resolution for tasks such as genotyping of recurrent parasitemias (20, 21) .
The detectability of a clone in a blood sample is determined by several factors, such as sensitivity of the molecular assay, biological features of the parasite (i.e., sequestration of synchronous clones and fluctuation of densities), and technical limitations. The contribution of each of these factors to a final genotyping result is challenging to disentangle. The improvements suggested for recrudescence typing will not lead to perfect detectability of parasite clones. This method will also not question previous results from earlier applications of genotyping in in vivo drug efficacy trials, but it provides a rational basis for a genotyping approach that is less prone to false outcomes by correcting a technical problem.
The WHO/Medicines for Malaria Venture (MMV) consultation (3) had suggested that genotyping should be performed in a sequential manner, starting with marker msp2 or glurp, and then as a third marker, msp1 was suggested. This decision was based on the workload incurred by markers for which more than one nested PCR needs to be performed. According to the present data, using glurp as the first marker in sequential genotyping likely leads to a stronger bias toward a "new infection." However, in many laboratories, msp2 followed by msp1 were used as the first and main markers. Therefore, our suggestion of a new genotyping approach will not dramatically change the PCR-corrected outcomes in future clinical trials compared to those of the past, but the precision will be improved. Despite the known shortfalls in genotyping, its application in field trial is indispensable, as in areas of intermediate transmission superinfections during the follow-up period of the trial will yield an incorrect high drug failure rate. In high-transmission settings, the numbers of superinfections are high and clone competition in PCR will be more dramatic. Thus, genotyping is bound to be more accurate than in areas of low and intermediate transmission. However, as multiplicity of infection is declining in most areas of endemicity in the world, the value of genotyping will increase in the future, as samples from the clinical trial areas will have fewer concurrent infections and thus less clone competition.
In conclusion, this study highlights major limitations of P. falciparum genotyping using length-polymorphic markers, which are caused by fragment size differences and intra-allelic family competition during nPCR. Our data suggest inclusion of both msp markers for genotyping of recurrent parasitemias and raises questions on the use of additional glurp genotyping. Relying solely on glurp genotyping should be discouraged due to the absence of allelic families and therefore direct template competition between all alleles. Small adjustments to the currently recommended genotyping procedures for clinical trials could significantly improve the accuracy of PCR correction of endpoints in malaria drug or vaccine efficacy trials.
MATERIALS AND METHODS
Culture strains and field samples. Four Plasmodium falciparum culture strains, HB3, 3D7, K1, and FCB1, were selected to represent the allelic families of msp1 and msp2 (Table 1) . DNA extractions from cultured parasites and blood from a human noninfected volunteer were performed using the QIAamp DNA blood minikit (Qiagen, Germany), and the DNA was stored at 4°C. Parasites were quantified by quantitative PCR targeting the P. falciparum 18S rRNA gene using a serial dilution of ring-stage parasites as quantification standards (22, 23) . DNA from 2 or 4 strains was mixed in human DNA, to reconstitute human blood, in ratios ranging from 1:1 to 5,000:1. For the minority clone, a minimal concentration of 10 parasite genomes per microliter of blood was chosen to prevent stochastic effects in positivity due to insufficient template in the PCR.
Genotyping was performed on 44 paired anonymous field samples. A sample pair consisted of a pretreatment sample and a sample collected on the day of recurrent parasitemia after antimalarial treatment. Mean time to recurrence was 14 days on average (range, 6 to 28 days). These samples were derived from clinical drug efficacy trials and had been collected at several sites across Africa and Asia. Therefore, a description of "overall" endemicity is not possible for the set of samples used. As a surrogate measure of transmission intensity, the mean multiplicity of infection (MOI) in baseline samples represents a useful parameter in the context of the present article. The mean MOI for marker msp2 at baseline was 2.3 concurrent infections per PCR-positive individual, with individual MOI ranging from 1 to 7 infections. Ethical clearance for genotyping of these anonymized blood samples was obtained from the Ethikkomission Nordwest-und Zentralschweiz (EKNZ Req-2016-00050).
Genotyping PCR and CE. Primer sequences, PCR mixtures, and cycling conditions are listed in Tables S1 and S2 in the supplemental material. The msp1 and msp2 primers correspond to the WHO recommended primers (17) , while glurp primary PCR (pPCR) and nPCR primers were optimized for CE in the present study. Allelic family-specific simplex and multiplex nPCRs were compared for marker msp2 using DNA from culture strain mixtures and field samples. Unless stated otherwise, results from allelic family-specific simplex nPCRs are reported. CE of markers msp1 and msp2 used the GeneScan 500 LIZ dye size standard (Thermo Fisher Scientific) on an AB3130xl automated sequencer. glurp fragment sizing was performed at Macrogen Corp (Amsterdam, The Netherlands) using the GeneScan 1200 LIZ dye size standard (Thermo Fisher Scientific). Fragment analysis was performed with GeneMapper software version 5 (Applied Biosystems). A peak height cutoff for minority clones was set at 10% of the height of the dominant peak for msp1 and msp2 genotyping. For genotyping of glurp, the cutoff was increased to 20% of the dominant peak to account for the characteristic high stutter peaks.
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